Are GLP-1s safe long term? What the longest trials show
Reviewed 21 sourcesPublished by PepVault
The longest GLP-1 trials ran 2 to 5.4 years, and heart events and deaths were the same or lower on the drug. The long-term risks, the thyroid warning, cycling.

- Last reviewed
- Sources
- 21
- Questions
- 7
- Compounds
- 5
The short answer
The longest GLP-1 trials followed people for 2 to 5.4 years, and heart attacks, strokes and deaths came out the same or lower on the drug than on placebo or an older GLP-1. The risks the labels warn about are stomach side effects, gallbladder problems, rare pancreatitis and, in diabetes, eye changes. The thyroid tumor warning comes from rodents. No label describes a cycle: they are written for continuous use.
- The longest trials ran two to five years; the longest, REWIND, ran a median 5.4 years.
- In the outcome trials, heart events were lower on the drug or no worse than an older GLP-1.
- Gallbladder problems rise with longer use; thyroid cancer is a rodent finding, unsettled in people.
- The labels describe weekly use with no end date and no off-weeks.
Evidence: Randomised trials in people lasting two to five years (outcome trials and long weight trials, all sponsored by the drugs' makers), a meta-analysis of 76 trials, three large health-record studies, the four FDA labels, an FDA safety review and a European Medicines Agency review; the thyroid tumor finding is from rodents.

How long are the longest GLP-1 trials?
The longest data come from outcome trials: large studies built to count heart attacks, strokes and deaths, so they keep thousands of people on the drug for years. The table gathers nine of the longest trials of GLP-1 drugs on sale today, each two years or more, with each one's length and what it found on safety, against placebo unless it says otherwise.
| Trial | Drug | Who took part | How long | What it found on safety |
|---|---|---|---|---|
| REWIND | Dulaglutide (Trulicity) | 9,901 adults with type 2 diabetes | Median 5.4 years | Heart events 12.0% vs 13.4%; stomach side effects 47.4% vs 34.1%12 |
| SOUL | Oral semaglutide (Rybelsus) | 9,650 adults with type 2 diabetes and heart or kidney disease | Median 49.5 months | Heart events 12.0% vs 13.8%; serious adverse events 47.9% vs 50.3%14 |
| SURPASS-CVOT | Tirzepatide (Mounjaro) vs dulaglutide | 13,299 adults with type 2 diabetes and heart disease | Median 210 weeks, about 4 years | Heart events 12.2% vs 13.1%, no worse than dulaglutide; more stomach side effects311 |
| LEADER | Liraglutide (Victoza) | 9,340 adults with type 2 diabetes | Median 3.8 years | Heart events 13.0% vs 14.9%; deaths 8.2% vs 9.6%; pancreatitis not higher6 |
| SELECT | Semaglutide 2.4 mg (Wegovy) | 17,604 adults with heart disease and overweight, no diabetes | Mean 39.8 months | Heart events 6.5% vs 8.0%; stopped for a side effect 16.6% vs 8.2%7 |
| FLOW | Semaglutide 1 mg (Ozempic) | 3,533 adults with type 2 diabetes and kidney disease | Median 3.4 years | Serious adverse events 49.6% vs 53.8%13 |
| SURMOUNT-1, 3-year part | Tirzepatide (Zepbound) | 1,032 adults with obesity and prediabetes | 176 weeks, then 17 weeks off | No new safety signals; stomach effects mostly in the first 20 weeks10 |
| SUSTAIN-6 | Semaglutide (Ozempic) | 3,297 adults with type 2 diabetes | 104 weeks | Heart events 6.6% vs 8.9%; more diabetic eye complications5 |
| STEP 5 | Semaglutide 2.4 mg (Wegovy) | 304 adults with obesity, no diabetes | 104 weeks | Stomach side effects 82.2% vs 53.9%, mostly mild to moderate9 |
Two points stand out. First, the drugs passed the test these trials were built for: none raised heart events, and most of the outcome trials lowered them. Second, the controlled record stops at about five years. Anything said about ten or twenty years of use rests on health-record studies, which can show a link but not prove a cause.
Long-term use is easier to review with your own record. PepVault logs each weekly dose and any side effect with its date and severity, so months of use sit in one place. Log it in PepVault

Did fewer people die on a GLP-1 in the long trials?
In several of them, yes. In LEADER, 8.2% of people on liraglutide died over the trial against 9.6% on placebo, and deaths from heart causes fell from 6.0% to 4.7%6. In SELECT, heart attacks, strokes and heart deaths together dropped from 8.0% to 6.5% in people without diabetes, a 20% lower risk7. In FLOW, deaths from any cause were 20% lower13; in REWIND the gap, 10.8% against 12.0%, was too small to rule out chance12. Over four years of SELECT, people on semaglutide also had fewer serious adverse events than those on placebo, in every weight group8.
Tirzepatide was tested against another GLP-1 instead of placebo. In SURPASS-CVOT it was no worse than dulaglutide on heart events, and fewer people died on it: 8.5% against 10.1%, a result the Mounjaro label marks as not controlled for multiple testing3. Weight loss also held: 10.2% below the starting weight at four years in SELECT8, and 12.3% to 19.7% at three years in SURMOUNT-1, depending on the dose10.
What are the long-term side effects of GLP-1s?
The trials found four that matter over years.
- Stomach side effects. Nausea, diarrhoea and vomiting are the most common, mostly while the dose is climbing. They are also the main reason people stop: in SELECT, 16.6% stopped for a side effect against 8.2% on placebo7.
- Gallbladder problems. Gallstones and gallbladder swelling (cholecystitis) are more common. Across 76 trials the risk was 37% higher on a GLP-1; the rise showed up with longer use, not shorter, and was largest in weight-loss trials15. In Wegovy's weight trials of the shot, gallstones were reported by 1.6% against 0.7% on placebo2.
- Pancreatitis. Inflammation of the pancreas is rare, and all four labels warn about it1234. In LEADER, it was not more common on liraglutide than on placebo6.
- Diabetic eye changes. In SUSTAIN-6, diabetic eye complications came to 3.0% on semaglutide against 1.8% on placebo, and the rise was larger in people who already had eye disease (8.2% against 5.2%) than in those without (0.7% against 0.4%). The label links it to blood sugar falling fast, which can briefly worsen the eyes1.
Commonly reported: in the open write-ups of 41 people who took semaglutide that our reports page counted (2019 to 2026), less appetite and weight loss led, and nausea or an upset stomach was the unwanted effect named most, 14 times20.
When to get help Wegovy's guide for patients says to stop the shot and call your prescriber right away for severe stomach pain that will not go away, sometimes felt through to the back; pain in the upper belly, a fever, or yellow skin or eyes are also reasons to call2.
Do GLP-1s cause thyroid cancer?
Each label opens with a boxed warning, the FDA's strongest label warning, on thyroid C-cell tumors. It comes from rodent studies: lifelong doses caused these tumors in mice and rats, at exposures close to what people get. Whether that happens in people is not known, and the labels say so1234.
| Label | Animals with tumors | In people | Who it rules out |
|---|---|---|---|
| Ozempic (June 2026) | Mice and rats | Unknown | Personal or family history of medullary thyroid cancer, or MEN 21 |
| Wegovy (June 2026) | Mice and rats | Unknown | The same2 |
| Mounjaro (Sept 2026) | Rats, both sexes | Unknown | The same3 |
| Zepbound (Sept 2026) | Rats | Unknown | The same4 |
Medullary thyroid cancer is a rare cancer of the C-cells, and MEN 2 is an inherited condition that causes it. Wegovy's label adds that cases have been reported in people on liraglutide, with data too thin to show or rule out a cause2.
Two large health-record studies point in different directions. A French study of people with diabetes found a higher thyroid cancer risk after 1 to 3 years of GLP-1 use (hazard ratio 1.58)16. A study across Denmark, Norway and Sweden of 145,410 people on a GLP-1, followed for a mean 3.9 years, found no rise (hazard ratio 0.93), compared with another diabetes drug17. The labels list the signs to report: a lump or swelling in the neck, hoarseness, trouble swallowing or shortness of breath2.
The tumor finding is from mice and rats. The labels say its relevance to people has not been determined, and that routine blood calcitonin tests or neck ultrasounds are of uncertain value for catching this cancer early2.
What changed in the GLP-1 labels in 2025 and 2026?
Three changes matter for long-term use. In January 2026, the FDA asked for the warning on suicidal behaviour and thoughts to come off the weight-loss labels: its review of 91 placebo-controlled trials in about 107,910 people found no raised risk21. Wegovy's and Zepbound's lists of recent changes mark it as removed in February 202624. In August 2026, Mounjaro's label added a use on the SURPASS-CVOT results: lowering the risk of heart attacks, strokes and heart deaths in adults with type 2 diabetes at high risk of them3.
In June 2025, the European Medicines Agency's safety committee concluded that NAION, a sudden loss of blood flow to the optic nerve that can affect sight, is a very rare side effect of semaglutide: up to 1 in 10,000 people, or about one extra case per 10,000 person-years of use19. The current US Ozempic and Wegovy labels do not list it12.
Do you need to cycle a GLP-1?
No label describes a cycle. A cycle means set weeks on a compound and then off, a habit borrowed from other peptides. Wegovy and Zepbound are approved to reduce weight and to "maintain weight reduction long term," with a weekly maintenance dose and no end date24. Ozempic and Mounjaro are diabetes drugs taken weekly for as long as they are prescribed13. None of the trials above tested on-and-off use.
Breaks have a cost the labels spell out. Semaglutide stays in the blood for about 5 weeks after the last dose1, and after two or more missed weekly doses, Wegovy's label restarts the dose climb at a lower dose to limit stomach side effects2. In the trials that stopped the drug, most of the lost weight came back within a year; our guide on stopping a GLP-1 has those numbers.
PepVault sends a reminder on your dose day, so a weekly shot is not missed by accident. Set reminders in PepVault
What is still unknown about long-term GLP-1 use?
Three things. The trials stop at about five years, so decades of use rest on health records. The rodent thyroid finding has not been settled in people. And the largest health-record map so far, of 215,970 US veterans with diabetes who started a GLP-1, found links in both directions: fewer cases of dementia, seizures, addiction and heart and metabolic disease, and more stomach problems, low blood pressure, fainting, arthritis, kidney stones and drug-related pancreatitis18. Those are associations, not proven effects.
Whether to stay on a GLP-1, and for how long, is a decision for you and your prescriber, who knows your history.
PepVault's doctor's report puts your doses, consistency, weight and logged side effects on one page to bring to that appointment. Track your weight in PepVault
Sources
- OZEMPIC (semaglutide) injection, prescribing information. Novo Nordisk. DailyMed, version 20, updated June 1, 2026 (published June 10, 2026). dailymed.nlm.nih.gov
- WEGOVY (semaglutide) injection and tablets, prescribing information and Medication Guide. Novo Nordisk. DailyMed, version 19, updated June 18, 2026 (published June 30, 2026). dailymed.nlm.nih.gov
- MOUNJARO (tirzepatide) injection, prescribing information. Eli Lilly. DailyMed, version 40, updated August 27, 2026 (published September 2, 2026). dailymed.nlm.nih.gov
- ZEPBOUND (tirzepatide) injection, prescribing information. Eli Lilly. DailyMed, version 40, updated August 28, 2026 (published September 2, 2026). dailymed.nlm.nih.gov
- Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016. PubMed 27633186
- Marso SP et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med. 2016. PubMed 27295427
- Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023. PubMed 37952131
- Ryan DH et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024. PubMed 38740993
- Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022. PubMed 36216945
- Jastreboff AM et al. Tirzepatide for obesity treatment and diabetes prevention (SURMOUNT-1, 3 years). N Engl J Med. 2025. PubMed 39536238
- Nicholls SJ et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes (SURPASS-CVOT). N Engl J Med. 2025. PubMed 41406444
- Gerstein HC et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet. 2019. PubMed 31189511
- Perkovic V et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med. 2024. PubMed 38785209
- McGuire DK et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes (SOUL). N Engl J Med. 2025. PubMed 40162642
- He L et al. Association of GLP-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022. PubMed 35344001
- Bezin J et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023. PubMed 36356111
- Pasternak B et al. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ. 2024. PubMed 38683947
- Xie Y et al. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat Med. 2025. PubMed 39833406
- European Medicines Agency. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy. June 6, 2025 (revised June 13, 2025). ema.europa.eu
- PepVault. Semaglutide: what people report (41 people's open write-ups, 2019 to 2026, counted November 19, 2026). pepvault.app
- US Food and Drug Administration. FDA requests removal of suicidal behavior and ideation warning from glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. Drug Safety Communication, January 13, 2026. fda.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.